Revenues (Details) $ in Thousands |
12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Mar. 16, 2021
USD ($)
|
Jan. 28, 2021
EUR (€)
|
Jan. 08, 2018 |
Mar. 31, 2015
USD ($)
|
Mar. 31, 2015
CAD ($)
|
Dec. 31, 2022
USD ($)
|
Dec. 31, 2022
CAD ($)
|
Dec. 31, 2022
EUR (€)
|
Dec. 31, 2019
USD ($)
|
|
| Revenues (Details) [Line Items] | |||||||||
| Payments | $ 1,292 | $ 1,650 | |||||||
| Additional payments (in Dollars) | $ 2,000 | ||||||||
| Payments percentage | 16.50% | 16.50% | |||||||
| Up-front amount receive | € 250 | $ 3,000 | |||||||
| Payables | 6,000 | ||||||||
| Amount received | 1,500 | $ 750 | |||||||
| Additional and payments | 500 | ||||||||
| Distribution and supply agreement, description | Under the Distribution and Supply Agreement, the Company is entitled to € 1,500 thousand upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) € 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and € 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between € 750 thousand and € 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between € 300 thousand and up to €4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson. | ||||||||
| Total payments | 750 | ||||||||
| Additional payments | $ 3,250 | ||||||||
| Royalties | 17.50% | 30.00% | |||||||
| Signature date | 2 years | ||||||||
| Royalities, description | 15%-40% royalties on net sales upon regulatory approval for veterinary use. | ||||||||
| Minimum [Member] | |||||||||
| Revenues (Details) [Line Items] | |||||||||
| Cost plus percentage | 10.00% | 10.00% | |||||||
| Maximum [Member] | |||||||||
| Revenues (Details) [Line Items] | |||||||||
| Cost plus percentage | 23.00% | 23.00% | |||||||
| Gebro Holding GmBH [Member] | |||||||||
| Revenues (Details) [Line Items] | |||||||||
| Amount received | $ 1,850 | € 1,500,000 | |||||||
| Additional and payments | 720 | € 600,000 | |||||||
| CMS Medical Venture Investment Limited [Member] | |||||||||
| Revenues (Details) [Line Items] | |||||||||
| Up-front amount receive | 2,000 | ||||||||
| Payables | 14,000 | ||||||||
| Amount received | 2,000 | ||||||||
| Milestone payments | 58,500 | ||||||||
| Ewopharma [Member] | |||||||||
| Revenues (Details) [Line Items] | |||||||||
| Up-front amount receive | $ 2,250 | ||||||||
| Payables | $ 40,450 | ||||||||
| Amount received | $ 2,250 | ||||||||